Niagen Bioscience Inc
NAGE | NASDAQ
$3.04
+$0.05 (+1.67%)
At close: Sep 21, 2026, 4:00 PM ET
$3.09
+$0.05 (+1.63%)
Pre-market:
Sep 22, 2026, 7:04 AM ET
Company Profile
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Key Executives
| Name | Position |
|---|---|
| Robert N. Fried | Chief Executive Officer & Director |
| Michiko Kelley | Chief Marketing Officer |
| Ozan Pamir | Chief Financial Officer & Principal Accounting Officer |
| Andrew Shao | Senior Vice President of Global Regulatory & Scientific Affairs |
| Carlos Lopez | Senior Vice President & General Counsel |
| Chu Yan | Managing Director of Asia Pacific |
| Frank Louis Jaksch Jr. | Co-Founder & Chairman |
| James Lee | Controller |
| Kendall Knysch | Head of Media Relations & Partnerships |
| Wesley Yu | Vice President of Finance |
Niagen Bioscience Inc
| Country | United States |
| IPO Date | Jun 23, 2015 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 117 |
| CEO | Robert N. Fried |
Contact Details
10900 Wilshire Blvd, Suite 600 Los Angeles,
California 90024 United States
Stock Details
| Ticker Symbol | NAGE |
| Exchange | NASDAQ |
| Fiscal Year | n/a |
| Reporting Currency | USD |
| CIK Code | 0001386570 |
| CUSIP Number | 171077407 |
| ISIN Number | US1710774076 |
| SIC Code | n/a |
Add to Watchlist
Select watchlists to add or remove NAGE